AIM: To investigate the antifibrotic effects of bone morphogenetic protein-7 (BMP-7) on Schistosoma japonicum (S. japonicum )-induced hepatic fibrosis in BALB/C mice. METHODS: Sixty BALB/C mice were randomly divided i...AIM: To investigate the antifibrotic effects of bone morphogenetic protein-7 (BMP-7) on Schistosoma japonicum (S. japonicum )-induced hepatic fibrosis in BALB/C mice. METHODS: Sixty BALB/C mice were randomly divided into three groups, including a control group (group A, n = 20), model group (group B, n = 20) and BMP-7 treated group (group C, n = 20). The mice in group B and group C were abdominally infected with S. japonicum cercariae to induce a schistosomal hepatic fibrosis model. The mice in group C were administered human recombinant BMP-7. Liver samples were extracted from mice sacrificed at 9 and 15 wk after modeling. Hepatic histopathological changes were assessed using Masson's staining. Transforming growth factor-beta 1 (TGF-β1), alpha-smooth muscle actin (α-SMA), phosphorylated Smad2/3 (pSmad2/3) and Smad7 protein levels and localization were measured by Western blotting and immunohistochemistry, respectively, and their mRNA expressions were detected by reverse transcriptionpolymerase chain reaction (RT-PCR). RESULTS: The schistosomal hepatic fibrosis mouse model was successfully established, as the livers of mice in group B and group C showed varying degrees of typical schistosomal hepatopathologic changes such as egg granuloma and collagen deposition. The degree of collagen deposition in group C was higher than that in group A (week 9: 22.95±6.66vs 2.02±0.76; week 15: 12.84±4.36 vs 1.74±0.80; P<0.05), but significantly lower than that in group B (week 9: 22.95±6.66 vs 34.43±6.96; week 15: 12.84±4.36 vs 18.90±5.07;P<0.05) at both time points. According to immunohistochemistry data, the expressions of α-SMA, TGF-β1 and pSmad2/3 protein in group C were higher than those in group A (α-SMA: week 9: 21.24±5.73 vs 0.33±0.20; week 15: 12.42±4.88 vs 0.34±0.27; TGF-β1: week 9: 37.00±13.74 vs 3.73±2.14; week 15: 16.71±9.80 vs 3.08±2.35; pSmad2/3: week 9: 12.92±4.81 vs 0.83±0.48; week 15: 7.87±4.09 vs 0.90±0.45; P<0.05), but significantly lower than those in group B (α-SMA: week 9: 21.2展开更多
目的观察黄芪注射液对糖尿病大鼠肾脏骨形成蛋白7(BMP-7)和结缔组织生长因子(CTGF)表达的影响。方法高脂高糖饲料喂养6周并注射STZ建立大鼠糖尿病模型,将成模的大鼠随机分为模型组和黄芪治疗组,并设正常对照组。各组大鼠干预8周。检测血...目的观察黄芪注射液对糖尿病大鼠肾脏骨形成蛋白7(BMP-7)和结缔组织生长因子(CTGF)表达的影响。方法高脂高糖饲料喂养6周并注射STZ建立大鼠糖尿病模型,将成模的大鼠随机分为模型组和黄芪治疗组,并设正常对照组。各组大鼠干预8周。检测血糖(BG),计算肾质量/体质量(KI),放射免疫法检测24 h尿蛋白排泄率(UAER),全自动生化分析仪检测血总胆固醇(TC)、三酰甘油(TG),免疫组化法测定大鼠肾脏BMP-7和CT-GF蛋白表达情况,实时荧光定量PCR法检测大鼠肾脏BMP-7和CTGF mRNA表达情况。结果与正常对照组相比,模型组KI、BG、TC、TG、UAER显著增高,肾组织BMP-7蛋白和mRNA表达均明显下降,CTGF蛋白和mRNA表达均明显升高;与模型组比较,黄芪治疗组TC、TG、KI及24 h UAER显著降低,肾组织BMP-7蛋白及mRNA表达升高,而CTGF蛋白及mRNA表达明显下调。结论黄芪注射液对糖尿病大鼠肾脏有保护作用,其机制可能与恢复肾组织BMP-7表达,降低肾组织CTGF过度表达有关。展开更多
背景:肝纤维化是一种由多种病因导致的以细胞外基质过度沉积为特点的慢性活动性疾病,目前中药治疗肝纤维化具有显著优势。研究表明丹参治疗肝纤维化具有较好的疗效,但其作用机制尚需进一步研究。目的:研究丹参酮ⅡA对肝纤维化大鼠肝脏...背景:肝纤维化是一种由多种病因导致的以细胞外基质过度沉积为特点的慢性活动性疾病,目前中药治疗肝纤维化具有显著优势。研究表明丹参治疗肝纤维化具有较好的疗效,但其作用机制尚需进一步研究。目的:研究丹参酮ⅡA对肝纤维化大鼠肝脏转化生长因子β-Smads信号通路相关因子转化生长因子β,骨形态发生蛋白7及Smad6,7基因表达的影响。方法:随机将SD大鼠分为正常对照组、模型组和丹参酮ⅡA治疗组,模型组和丹参酮ⅡA治疗组给予橄榄油稀释的体积分数10%四氯化碳5 m L/kg皮下注射,每周2次,共8周,建立肝纤维化模型。建模后第4周,丹参酮ⅡA治疗组给予丹参酮ⅡA治疗至第8周。正常对照组以同样方法皮下注射橄榄油。结果与结论:Western印迹检测和RT-PCR检测显示,与正常对照组相比,模型组大鼠肝组织转化生长因子β的表达明显增加(P<0.01),而其抑制因子骨形态发生蛋白7和Smad6,7的表达明显减少(P<0.01),丹参酮ⅡA可明显逆转上述因子的表达(P<0.01)。结果提示,丹参酮ⅡA治疗肝纤维化可能与其抑制转化生长因子β,增加其抑制因子骨形态发生蛋白7和Smad6,7的表达有关。展开更多
文摘AIM: To investigate the antifibrotic effects of bone morphogenetic protein-7 (BMP-7) on Schistosoma japonicum (S. japonicum )-induced hepatic fibrosis in BALB/C mice. METHODS: Sixty BALB/C mice were randomly divided into three groups, including a control group (group A, n = 20), model group (group B, n = 20) and BMP-7 treated group (group C, n = 20). The mice in group B and group C were abdominally infected with S. japonicum cercariae to induce a schistosomal hepatic fibrosis model. The mice in group C were administered human recombinant BMP-7. Liver samples were extracted from mice sacrificed at 9 and 15 wk after modeling. Hepatic histopathological changes were assessed using Masson's staining. Transforming growth factor-beta 1 (TGF-β1), alpha-smooth muscle actin (α-SMA), phosphorylated Smad2/3 (pSmad2/3) and Smad7 protein levels and localization were measured by Western blotting and immunohistochemistry, respectively, and their mRNA expressions were detected by reverse transcriptionpolymerase chain reaction (RT-PCR). RESULTS: The schistosomal hepatic fibrosis mouse model was successfully established, as the livers of mice in group B and group C showed varying degrees of typical schistosomal hepatopathologic changes such as egg granuloma and collagen deposition. The degree of collagen deposition in group C was higher than that in group A (week 9: 22.95±6.66vs 2.02±0.76; week 15: 12.84±4.36 vs 1.74±0.80; P<0.05), but significantly lower than that in group B (week 9: 22.95±6.66 vs 34.43±6.96; week 15: 12.84±4.36 vs 18.90±5.07;P<0.05) at both time points. According to immunohistochemistry data, the expressions of α-SMA, TGF-β1 and pSmad2/3 protein in group C were higher than those in group A (α-SMA: week 9: 21.24±5.73 vs 0.33±0.20; week 15: 12.42±4.88 vs 0.34±0.27; TGF-β1: week 9: 37.00±13.74 vs 3.73±2.14; week 15: 16.71±9.80 vs 3.08±2.35; pSmad2/3: week 9: 12.92±4.81 vs 0.83±0.48; week 15: 7.87±4.09 vs 0.90±0.45; P<0.05), but significantly lower than those in group B (α-SMA: week 9: 21.2
文摘目的观察黄芪注射液对糖尿病大鼠肾脏骨形成蛋白7(BMP-7)和结缔组织生长因子(CTGF)表达的影响。方法高脂高糖饲料喂养6周并注射STZ建立大鼠糖尿病模型,将成模的大鼠随机分为模型组和黄芪治疗组,并设正常对照组。各组大鼠干预8周。检测血糖(BG),计算肾质量/体质量(KI),放射免疫法检测24 h尿蛋白排泄率(UAER),全自动生化分析仪检测血总胆固醇(TC)、三酰甘油(TG),免疫组化法测定大鼠肾脏BMP-7和CT-GF蛋白表达情况,实时荧光定量PCR法检测大鼠肾脏BMP-7和CTGF mRNA表达情况。结果与正常对照组相比,模型组KI、BG、TC、TG、UAER显著增高,肾组织BMP-7蛋白和mRNA表达均明显下降,CTGF蛋白和mRNA表达均明显升高;与模型组比较,黄芪治疗组TC、TG、KI及24 h UAER显著降低,肾组织BMP-7蛋白及mRNA表达升高,而CTGF蛋白及mRNA表达明显下调。结论黄芪注射液对糖尿病大鼠肾脏有保护作用,其机制可能与恢复肾组织BMP-7表达,降低肾组织CTGF过度表达有关。
文摘背景:肝纤维化是一种由多种病因导致的以细胞外基质过度沉积为特点的慢性活动性疾病,目前中药治疗肝纤维化具有显著优势。研究表明丹参治疗肝纤维化具有较好的疗效,但其作用机制尚需进一步研究。目的:研究丹参酮ⅡA对肝纤维化大鼠肝脏转化生长因子β-Smads信号通路相关因子转化生长因子β,骨形态发生蛋白7及Smad6,7基因表达的影响。方法:随机将SD大鼠分为正常对照组、模型组和丹参酮ⅡA治疗组,模型组和丹参酮ⅡA治疗组给予橄榄油稀释的体积分数10%四氯化碳5 m L/kg皮下注射,每周2次,共8周,建立肝纤维化模型。建模后第4周,丹参酮ⅡA治疗组给予丹参酮ⅡA治疗至第8周。正常对照组以同样方法皮下注射橄榄油。结果与结论:Western印迹检测和RT-PCR检测显示,与正常对照组相比,模型组大鼠肝组织转化生长因子β的表达明显增加(P<0.01),而其抑制因子骨形态发生蛋白7和Smad6,7的表达明显减少(P<0.01),丹参酮ⅡA可明显逆转上述因子的表达(P<0.01)。结果提示,丹参酮ⅡA治疗肝纤维化可能与其抑制转化生长因子β,增加其抑制因子骨形态发生蛋白7和Smad6,7的表达有关。
